Skip to main content
Clinical Trials/NCT01189877
NCT01189877CompletedNot Applicable

Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins

Memorial Sloan Kettering Cancer Center1 site in 1 country30 target enrollmentStarted: August 2010Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
30
Locations
1
Primary Endpoint
Measure pO2 in rectal cancers

Study Overview

Brief Summary

The purpose of this study is to see if the cells in rectal cancer are oxygen-starved, or hypoxic. We know that as cancers grow bigger, parts of them are cut off from the oxygen supply and they become hypoxic, basically, lacking oxygen. Research has shown that cells that are oxygen-starved respond differently to treatment such as chemotherapy and radiation when compared to cells that are oxygen rich.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 89 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Biopsy proven adenocarcinoma of the rectum. If a biopsy was taken at an outside hospital, the slides and diagnosis will be reviewed and confirmed by a pathologist at MSKCC.
  • Mid to distal rectal tumors not requiring pre-op radiation or chemotherapy
  • Age < 90
  • Karnofsky performance status ≥ 60
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Current pregnancy
  • Uncontrolled intercurrent illness that would limit compliance with study requirements.

Outcomes

Primary Outcomes

Measure pO2 in rectal cancers

Time Frame: 2 years

Measure pO2 in rectal cancers

Secondary Outcomes

  • Correlate immunohistochemical analysis of endogenous markers of hypoxia(2 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Characterization of Rectal Cancer Hypoxia... | Clinical Trial